Basic Information
RNALocate ID: | RLID:11001824 |
RNA Symbol: | hsa-miR-152-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-152-3p |
RNA ID: | miRBase:MIMAT0000438 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22211110 |
Tissue/Cell Line: | Breast milk |
Method: | Next-generation RNA sequencing |
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001792 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001793 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001794 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001795 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001796 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:11001822 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001823 | Exosome | Ovarian follicular fluid | 22116803 |
RLID:11001825 | Exosome | Brain tissue | 23382797 |
RLID:11001826 | Exosome | Plasma | 23663360 |
RLID:11001827 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001828 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000087 | Exosome | Breast milk|Tongue tissue | |
RLID-D:11000366 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-152-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-17001 |
MNDR | hsa-miR-152-3p | Oral squamous cell carcinoma | MNDR-E-MI-17002 |
MNDR | hsa-miR-152-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-17003 |
MNDR | hsa-miR-152-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-17004 |
MNDR | hsa-miR-152-3p | Lymphoma | MNDR-E-MI-17005 |
MNDR | hsa-miR-152-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-17006 |
MNDR | hsa-miR-152-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-17007 |
MNDR | hsa-miR-152-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-17008 |
MNDR | hsa-miR-152-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-17009 |
MNDR | hsa-miR-152-3p | Her2-receptor positive breast cancer | MNDR-E-MI-17010 |
MNDR | hsa-miR-152-3p | Niemann-pick disease type c | MNDR-E-MI-17011 |
MNDR | hsa-miR-152-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-17012 |
MNDR | hsa-miR-152-3p | Prostate cancer | MNDR-E-MI-17013 |
MNDR | hsa-miR-152-3p | Gastric cancer | MNDR-E-MI-17014 |
MNDR | hsa-miR-152-3p | Alzheimer disease | MNDR-E-MI-17015 |
MNDR | hsa-miR-152-3p | Bladder cancer | MNDR-E-MI-17016 |
MNDR | hsa-miR-152-3p | Dysautonomia familial | MNDR-E-MI-17017 |
MNDR | hsa-miR-152-3p | Head and neck cancer | MNDR-E-MI-17018 |
MNDR | hsa-miR-152-3p | Dengue disease | MNDR-E-MI-17019 |
MNDR | hsa-miR-152-3p | Cardiovascular disease | MNDR-E-MI-17020 |
MNDR | hsa-miR-152-3p | Carotid stenosis | MNDR-E-MI-17021 |
MNDR | hsa-miR-152-3p | Brain cancer | MNDR-E-MI-17022 |
MNDR | hsa-miR-152-3p | Lung cancer | MNDR-E-MI-17023 |
MNDR | hsa-miR-152-3p | Endometrial cancer | MNDR-E-MI-17024 |
MNDR | hsa-miR-152-3p | Parkinson disease | MNDR-E-MI-17025 |
MNDR | hsa-miR-152-3p | Niemann-pick disease | MNDR-E-MI-17026 |
MNDR | hsa-miR-152-3p | Breast cancer | MNDR-E-MI-17027 |
MNDR | hsa-miR-152-3p | Thyroid cancer | MNDR-E-MI-17028 |
MNDR | hsa-miR-152-3p | Pancreatic cancer | MNDR-E-MI-17029 |
MNDR | hsa-miR-152-3p | Malignant melanoma | MNDR-E-MI-17030 |
MNDR | hsa-miR-152-3p | Gaucher disease | MNDR-E-MI-17031 |
MNDR | hsa-miR-152-3p | Rectum adenocarcinoma | MNDR-E-MI-17032 |
MNDR | hsa-miR-152-3p | Nephroblastoma | MNDR-E-MI-17033 |
MNDR | hsa-miR-152-3p | Colon cancer | MNDR-E-MI-17034 |
MNDR | hsa-miR-152-3p | Colon adenocarcinoma | MNDR-E-MI-17035 |
MNDR | hsa-miR-152-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-17036 |
MNDR | hsa-miR-152-3p | Familial ovarian cancer | MNDR-E-MI-17037 |
MNDR | hsa-miR-152-3p | Prostate adenocarcinoma | MNDR-E-MI-17038 |
MNDR | hsa-miR-152-3p | Hematologic cancer | MNDR-E-MI-17039 |
MNDR | hsa-miR-152-3p | Carcinoma ductal breast | MNDR-E-MI-17040 |
MNDR | hsa-miR-152-3p | Glioblastoma | MNDR-E-MI-17041 |
MNDR | hsa-miR-152-3p | Glioma | MNDR-E-MI-17042 |
MNDR | hsa-miR-152-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-17043 |
MNDR | hsa-miR-152-3p | Meningioma | MNDR-E-MI-17044 |
MNDR | hsa-miR-152-3p | Liver neoplasms | MNDR-E-MI-17045 |
MNDR | hsa-miR-152-3p | Cervical adenocarcinoma | MNDR-E-MI-17046 |
MNDR | hsa-miR-152-3p | Gastric adenocarcinoma | MNDR-E-MI-17047 |
MNDR | hsa-miR-152-3p | Lung carcinoma | MNDR-E-MI-17048 |
MNDR | hsa-miR-152-3p | Lung squamous cell carcinoma | MNDR-E-MI-17049 |
MNDR | hsa-miR-152-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-17050 |
MNDR | hsa-miR-152-3p | Lung adenocarcinoma | MNDR-E-MI-17051 |
MNDR | hsa-miR-152-3p | Thyroid carcinoma | MNDR-E-MI-17052 |
MNDR | hsa-miR-152-3p | Ovarian carcinoma | MNDR-E-MI-17053 |
MNDR | hsa-miR-152-3p | Bladder urothelial carcinoma | MNDR-E-MI-17054 |
MNDR | hsa-miR-152-3p | Pancreatic adenocarcinoma | MNDR-E-MI-17055 |
MNDR | hsa-miR-152-3p | Carcinoma renal cell | MNDR-E-MI-17056 |
MNDR | hsa-miR-152-3p | Renal clear cell carcinoma | MNDR-E-MI-17057 |
MNDR | hsa-miR-152-3p | Cholangiocarcinoma | MNDR-E-MI-17058 |
MNDR | hsa-miR-152-3p | Esophageal cancer | MNDR-E-MI-17059 |
MNDR | hsa-miR-152-3p | Liver cirrhosis | MNDR-E-MI-17060 |
MNDR | hsa-miR-152-3p | Lung small cell carcinoma | MNDR-E-MI-17061 |
MNDR | hsa-miR-152-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-17062 |
MNDR | hsa-miR-152-3p | Breast invasive carcinoma | MNDR-E-MI-17063 |
MNDR | hsa-miR-152-3p | Early hepatocellular carcinoma | MNDR-E-MI-17064 |
MNDR | hsa-miR-152-3p | Familiar ovarian carcinoma | MNDR-E-MI-17065 |
MNDR | hsa-miR-152-3p | B-cell lymphoma | MNDR-E-MI-17066 |
MNDR | hsa-miR-152-3p | Rheumatoid arthritis | MNDR-E-MI-17067 |
MNDR | hsa-miR-152-3p | Neuroblastoma | MNDR-E-MI-17068 |
MNDR | hsa-miR-152-3p | Chronic fatigue syndrome | MNDR-E-MI-17069 |
MNDR | hsa-miR-152-3p | Hodgkin lymphoma | MNDR-E-MI-17070 |
MNDR | hsa-miR-152-3p | Neuromyelitis optica | MNDR-E-MI-17071 |
MNDR | hsa-miR-152-3p | Acute myeloid leukemia | MNDR-E-MI-17072 |
MNDR | hsa-miR-152-3p | Colorectal cancer | MNDR-E-MI-17073 |
MNDR | hsa-miR-152-3p | Nasopharynx carcinoma | MNDR-E-MI-17074 |
MNDR | hsa-miR-152-3p | Type 2 diabetes mellitus | MNDR-E-MI-17075 |
MNDR | hsa-miR-152-3p | Acute lymphocytic leukemia | MNDR-E-MI-17076 |
MNDR | hsa-miR-152-3p | Ovarian epithelial cancer | MNDR-E-MI-17077 |
MNDR | hsa-miR-152-3p | Nasopharyngeal cancer | MNDR-E-MI-17078 |
MNDR | hsa-miR-152-3p | Prostatic neoplasms | MNDR-E-MI-17079 |
MNDR | hsa-miR-152-3p | Epstein-barr virus infections | MNDR-E-MI-17080 |
MNDR | hsa-miR-152-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-17081 |
MNDR | hsa-miR-152-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-17082 |
MNDR | hsa-miR-152-3p | Stroke lacunar | MNDR-E-MI-17083 |
MNDR | hsa-miR-152-3p | Breast cancer her3+ negative | MNDR-E-MI-17084 |
MNDR | hsa-miR-152-3p | High grade dysplastic nodule | MNDR-E-MI-17085 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ADAM17 | Homo sapiens | RR00040511 |
TOP